Fig. 2: Patients receiving PGT experienced a clinical response.

a, Waterfall plot for 31 CNS tumors with measurable disease at the start of a PGT. Treatment response was evaluated using the RANO criteria. The dotted lines at 25% and −50% delineate the category of response (≥25%, PD; 25 to −50%, SD; −50% or lower to −99%, PR; −100%, CR). b, Waterfall plot for 35 solid tumors with measurable disease at the start of a PGT. Treatment response was evaluated using the RECIST or PERCIST criteria. The dotted lines at 25% and −30% delineate the category of response (≥25%, PD; 25 to −30%, SD; −30% or lower to −99%, PR; −100%, CR). c, Response according to cancer type to 70 PGTs given with measurable disease. d, Response according to cancer type to 90 PGTs with evaluable disease (70 measurable and 20 non-measurable). e, OCB rate in 97 PGTs. OCB was defined as CR, PR and SD of 24 weeks’ duration or longer. f, PFS ratio for 31 PGTs. The PFS ratio was defined as the PFS duration of the PGT to that of a previous treatment in the same patient. A PFS ratio greater than 1.3 (above the dotted line) represents prolongation of the progression-free period for more than 30% by the PGT compared to a previous treatment. The color of the dots denotes the clinical course. g,h, PFS (g) and OS (h) stratified according to PFS ratio. A two-sided log-rank test was used to compare the Kaplan–Meier survival curves.